Table 2

Effect of varying single or multiple daily doses of squalamine combined with paclitaxel plus carboplatin on growth of the MV-522 human lung tumor xenograft in nude mice

Each treatment group consisted of 10 mice. The % TGI was calculated using the final mean excised tumor weight for each treatment group rather than the final tumor weights estimated by dimensional measurement. The squalamine dose as listed was administered on a daily basis as a split dose.
GroupDose (mg/kg/day)Route & schedule% weight change (day 32)Final excised tumor weight (mg) (mean ± SE)% TGIMice with tumor shrinkage (day 32)Mean % tumor shrinkageMice with complete shrinkage
ControlVehiclei.p.: b.i.d. days 1–5, 8–9+7.9%739.2 ± 69.400
Paclitaxel10i.p.: q.d. × 5a
 + carboplatin20i.p.: q.d. × 5+8.6%288.5 ± 76.466.9%b00
Paclitaxel10i.p.: q.d. × 5
 + carboplatin20i.p.: q.d. × 5
 + squalamine0.2i.p.: b.i.d. day 5+6.1%263.0 ± 81.770.7%b246.4%0
Paclitaxel10i.p.: q.d. × 5
 + carboplatin20i.p.: q.d. × 5
 + squalamine2.0i.p.: b.i.d. day 5+8.6%274.2 ± 91.269.0%b250.4%0
Paclitaxel10i.p.: q.d. × 5
 + carboplatin20i.p.: q.d. × 5
 + squalamine10i.p.: b.i.d. day 5+11.9176.9 ± 49.783.2%b321.0%0
Paclitaxel10i.p.: q.d. × 5
 + carboplatin20i.p.: q.d. × 5
 + squalamine20i.p.: bid day 5−11.9%161.7 ± 64.685.7%b445.1%1
Paclitaxel10i.p.: q.d. × 5
 + carboplatin20i.p.: q.d. × 5
 + squalamine0.2i.p.: bid days 1–5, 8–9+8.3%195.8 ± 40.480.4%b255.2%0
Paclitaxel10i.p.: q.d. × 5
 + carboplatin20i.p.: q.d. × 5
 + squalamine2.0i.p.: b.i.d. days 1–5, 8–9+12.6%88.0 ± 18.996.6%c446.9%0
Paclitaxel10i.p.: q.d. × 5
 + carboplatin20i.p.: q.d. × 5
 + squalamine10i.p.: b.i.d. days 1–5, 8–9+4.7%98.4 ± 28.594.9%c541.3%0
Paclitaxel10i.p.: q.d. × 5
 + carboplatin20i.p.: q.d. × 5
 + squalamine20i.p.: b.i.d. days 1–5, 8–9+0.5%142.1 ± 37.988.6%c317.8%0
  • a × 5, for 5 days.

  • b P < 0.05 relative to control.

  • c P < 0.05 relative to carboplatin/paclitaxel group.